Archives

by in
Entry Author Date Location
Shire Pays Over $260M Upfront in IPO Detour for San Diego’s Lumena 05/12/14 National
San Diego Life Sciences Roundup: Isis, Receptos, Suneva, and More 01/17/14 San Diego
Dicerna Snags $60M as RNAi Heats Up Again 08/01/13 Boston
Has The Pendulum Swung Too Far in Favor of Rare Diseases? 03/14/13 Seattle
Biogen ALS Failure Highlights Clinical Trial Frustrations 01/10/13 Boston
Shire Buys Third Rock’s Lotus Tissue Repair 01/08/13 Boston
Synageva BioPharma Announces $80 Million Stock Offering 01/03/13 Boston
Pfizer, Cystic Fibrosis Foundation in $58 Million Pact 11/19/12 New York
Biotech Racking Up Successes Against Ultra-Orphan Diseases 10/15/12 New York
Xconomist of the Week: Evan Snyder—Stem Cell Reality Check 05/25/12 San Diego
Roche Embraces Three-Way Rare-Disease Play With PTC and Patient Group 11/30/11 New York
NPS Re-Jiggers Glaxo Partnership, Finds Value in Ultra-Orphan Diseases 08/09/11 New York
Page 1 of 1